PULMATRIX, INC. Restricted Cash, Current
PULMATRIX, INC. (PULM) had Restricted Cash, Current of $700.00 thousand as of 2026-06-30, per its S-4/A filed 2026-09-17.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-09-17
- 2026-06-30: Restricted Cash, Current $700.00K.
- 2026-03-31: Restricted Cash, Current $700.00K.
- 2024-06-30: Restricted Cash, Current $1.42M.
- 2023-09-30: Restricted Cash, Current $153.00K.
| Period end | Restricted Cash, Current |
|---|---|
| 2026-06-30 | $700.00K S-4/A · filed 2026-09-17 |
| 2026-03-31 | $700.00K S-4/A · filed 2026-08-03 |
| 2024-06-30 | $1.42M 10-Q · filed 2025-08-06 |
| 2023-09-30 | $153.00K 10-Q · filed 2024-11-08 |
| 2023-06-30 | $153.00K 10-Q · filed 2024-08-13 |
| 2023-03-31 | $153.00K 10-Q · filed 2024-05-10 |
| 2022-12-31 | $153.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $153.00K 10-Q · filed 2023-11-09 |
| 2022-06-30 | $153.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |